



Public Health
England



NHS England
NHS Improvement

CADEAS Work Programme 2021/22



Background

- CADEAS (Cancer Alliance Data, Evaluation and Analysis Service) is funded by the National Cancer Programme, and is a collaboration between NHS England/Improvement, and Public Health England.
- The aim of CADEAS is to support Cancer Alliances to take a data-driven, and evidence-based approach to:
 - a) Recovering Cancer services following the Covid-19 pandemic;
 - b) Meeting and sustaining operational performance; and
 - c) Transforming Cancer services to meet the ambitions in the Long Term Plan.

Our core offer to Cancer Alliances is to:

- Provide access to timely and reliable data held nationally on operational performance and cancer activities, outputs and outcomes to track progress and to identify areas for action;
 - Provide products such as tools, models and analysis to give greater depth and insights into key priority areas;
 - Offer advice and guidance to support robust local evaluations; and
 - Synthesise emerging evidence and disseminate evaluation findings to understand what works and how.
-
- This CADEAS work programme for 2021/22 was developed following stakeholder engagement, including with Cancer Alliances; NCRAS (National Cancer Registration Analysis Service); and teams across the National Cancer Programme.
 - The work programme will be reviewed throughout the year to ensure CADEAS products continue to provide maximum value.

Reflections on 2020/21

Key achievements 2020/21

Restoration and Recovery of Cancer services

CADEAS played a pivotal role in supporting the restoration and recovery of Cancer services following the Covid pandemic through:

- Producing **weekly and monthly data packs** on how cancer services were performing in terms of referrals, treatments and backlog.
- Producing monthly **equity packs** on the impact of Covid on referrals and treatment for different segments of the population (by ethnicity; deprivation; age; sex).
- Modelling the **projected impact of Covid on Cancer services** at an Alliance level.
- Collecting **surgical hub data** and sharing **data on cancellations**.
- **Understanding the cohort of patients who would have been expected to start treatment during Covid, and didn't.**
- **Exploring the relationship between local restrictions; Covid hospital admissions; and Cancer services.**

Operational Performance

Worked in partnership with NHSE/I's Performance Analysis Team (PAT) to:

- Provide **monthly Cancer Waiting Times (CWT) data extracts** to Cancer Alliances.
- Report on **Faster Diagnosis Standard (FDS) data completeness and performance.**
- Report on **62-day CWTs** for each Cancer Alliance by provider and tumour group.

Worked with NCRAS to:

- Produce tumour specific **Two Week Wait (TWW) conversion and detection rates** using linked CWTs and registry data.

Key achievements 2020/21 cont.

Screening

- **Shared monthly screening reports** produced by NHS PAT team for performance and monitoring use.

Earlier and Faster Diagnosis

- Examined the **median length of different parts of the patient pathway**. This expanded earlier work to look at a fuller set of tumour groups/sites. A visualisation tool was developed to facilitate exploration of the data.
- Supported the **evaluation of the Targeted Lung Health Check (TLHC) programme**, providing evaluation expertise to help ensure the evaluation adequately answers the key questions to inform implementation. A qualitative report summarising interviews with key staff was delivered. The contract was amended to incorporate a further number of sites and the collection of management information commenced.
- Commissioned the **evaluation of Rapid Diagnostic Centres (RDCs)**; data solution established; and a 1st qualitative report summarising interviewed with key staff was received.
- The **evaluation of the Colon Capsule Endoscopy (CCE)** was scoped; contractor identified; preparation work completed to collect management information and undertake service evaluation consisting of interviews with staff.
- Developed a **monitoring and evaluation framework for faecal immunochemical testing (FIT)**.

Experience of Care

- Triangulated **Cancer Patient Experience Survey (CPES) data** with CADEAS data products to understand correlations and gaps.

Key achievements 2020/21 cont.

Personalised Care

- Provided advice on the different **metrics to monitor Personalised Care**.
- Worked with an external partner to deliver a **qualitative process evaluation of Personalised Stratified Follow Up (PSFU)**.
- Produced a **feasibility study for undertaking an impact evaluation of PSFU**.

Innovation

- Scoped out an **evaluation for Cytosponge**. Specification out to tender.
- Produced **guidance to support Alliances in undertaking local evaluations of innovations**.

Other

- Contributed to the **development of NHS Digital's Trusted Research Environment (TRE)**. Testing the usability of the platform by taking forward it's 1st project through the evaluation of Rapid Diagnostic Centres (RDCs). Memorandum of Understanding established between NHSE/I and NHSD.
- Established the **Evaluation Oversight Group (EOG)** – a sub-group of the Cancer Data Analysis Advisory Group (CDAAG) to provide support, scrutiny and advice to the evaluation of key Cancer Programme interventions.
- Supported NCRAS with a number of **ODR requests**.
- **User testing of the Rapid Registration Dataset**.
- **Regular engagement with Alliances**: regional analyst calls; monthly product mail; webinars; national analyst event.

Access to CADEAS products

Products most downloaded from the CADEAS website:

- Cancer Equity data packs
- Covid 19 data packs
- Cancer demand backlog model
- CADEAS work programme
- Pathway length percentiles
- Provider by tumour dashboard

Findings from consultation with Alliances

- Alliance analyst survey in Dec 2020/Jan 2021.
- Response rate was impacted by Covid, but 13 responses were received and a couple more via follow-up e-mails and calls.
- Further feedback still welcome.

Headline findings:

Overall tone of responses was positive

Good awareness of data products. Less awareness of evaluation work

Key resources noted as being: Covid data packs; equity packs; CWT products.

Welcomed the greater number of webinars and found virtual calls more convenient than face-to-face. Thought this had increased engagement.

A common ask was for CADEAS to provide data at a more granular level e.g. CCG/PCN (to help local implementation).

Receiving more up-to-date data has been hugely valued. BUT – it has also changed the expectation for other products. There is a huge appetite for more real-time data going forward.

Keenness to see the results of the evaluation projects at an Alliance level.

Work programme 2021/22

Priorities for CADEAS 2021/22

1. Supporting the recovery of Cancer services from the Covid pandemic
2. Operational performance
3. System intelligence
4. Understanding Health Inequalities in Cancer services
5. Evaluation of key interventions

1. Supporting the recovery of Cancer services from the Covid pandemic

- Continue to produce **weekly and monthly data packs** on how Cancer services are performing in terms of referrals, treatments and backlog;
- Continue to **understand the cohort of patients who would have been expected to start treatment** during Covid, and haven't.
- Continue to provide **ad hoc analytical support to the Cancer Programme** to inform national and local recovery.
- Understand the **impact of Covid on Long Term Plan TP (LTP) priorities** by:
 1. Working with NCRAS to **provide Alliance level breakdowns from the Rapid Registration Dataset** (including staging)
 2. Updating the **Early diagnosis tool** to enable Alliances to understand how Covid has impacted on their early diagnosis and survival trajectories.
 3. Updating the **RDC Demand and Capacity** model.

** See later slide re continued work on how Covid has impacted Health Inequalities in Cancer services.*

2. Operational Performance

- **Dedicated FTE analyst to support the Operational Performance team** to monitor key performance measures and ensure quality data is produced and fed into discussions with Alliances.
- Continue to work with NHSE/I's Performance Analysis Team (PAT) to:
 - Provide monthly **Cancer Waiting Times (CWT) data extracts** to Cancer Alliances.
 - Report on **Faster Diagnosis Standard (FDS) data completeness and performance.**
 - Report on **62-day CWTs.**

3. System Intelligence

- Re-establish **summary indicator grids** (shift from monthly to quarterly and incorporating new 'Living With and Beyond Cancer' – LWBC and 'Quality of Life' – QOL measures).
- Assess **Sustainability and Transformation Plans (STP) trajectories** for 21/22.
- Continue to share monthly **screening reports** produced by NHS PAT for performance and monitoring use.
- Update the previous CADEAS **briefing on survival levels by Alliance**.
- Update previous analysis on the **best practice timed pathway: urgent referral to 1st diagnostic endoscopy**.
- Collaborate with Analytical Services and NCRAS to better understand **treatment variation** (specifically treatment modality and clinical trials by survival).
- Update the **median pathways tool** to understand the median lengths of different parts of the Cancer pathway.

3. System Intelligence – project plan

DELIVERABLES													
Project	Activity/deliverable	Q1			Q2			Q3			Q4		
		April	May	June	July	Aug	Sept	Oct	Nov	Dec	Jan	Feb	March
Summary indicator grids	Publish existing indicators			✓			✓			✓			✓
	Support for the quarterly assurance process												
CADEAS product mail	Send product mail to Alliances and Cancer Programme	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Assess STP plan trajectories	Review STP plans and flag issues to CASE team												
NHSE&I PAT screening report	Circulate report to Alliances	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Survival analyses	Update survival data by Cancer Alliance												
	Publish updated survival report		✓										
Best practice timed pathway: urgent referral to 1st diagnostic endoscopy	Analyse urgent referral to 1st diagnostic endoscopy												
	Publish analysis of urgent referral to 1st diagnostic endoscopy		✓										
Median Pathways	Undertake analysis of median pathway lengths												
	Publish median pathways analysis											✓	
Treatment variation analysis	Treatment modality survival figures, broken down by tumour modality; cancer stage; and Alliance												
	Report outlining treatment modality survival figures, broken down by tumour modality; cancer stage; and Alliance						✓						
	Explore the relationship between clinical trials recruitment and survival, by Cancer Alliance												
	Report outlining the relationship between clinical trials recruitment and survival by Cancer Alliance									✓			

4. Understanding Health Inequalities

- Continue to monitor the **impact of Covid on referrals and treatment in terms of deprivation; ethnicity; age and sex** to inform how services are restored and recovered following the Covid Pandemic. Publish monthly data packs for Alliances (at an Alliance and CCG level), and publicly (at a regional level).
- **Explore the availability and usefulness of data on other Health Inequality dimensions** e.g. faith; homelessness; mental health; refugees and asylum seekers; traveller communities
- Explore **inequalities at different parts of the Cancer pathway** (covering smoking prevalence; screening; emergency presentation; early stage diagnosis; survival; patient experience). Publish data in CancerStats2.
- Work with other Health Inequality analysts across NHSE/I and NCRAS to ensure a consistent methodological approach, and appropriate data is presented in the NHSE/I **Recovery of Critical Services (RCS) and Viewpoint dashboards**.

5. Evaluation of key interventions

- Continue to support the **evaluation of the Targeted Lung Health Check (TLHC) programme**. Quality assurance of monthly management information reports and quarterly evaluation reports.
- Continue to support the **evaluation of Rapid Diagnostic Centres (RDCs)**. Work closely with NHS Digital to ensure the data solution (of using the Trusted Research Environment) for the impact evaluation element, works smoothly. Quarterly evaluation reports.
- Support and undertake the **Colon Capsule Endoscopy (CCE) evaluation**. Commission out the impact evaluation; collect and report on monthly management information; undertake a service evaluation consisting of interviews with staff; commission out a patient experience evaluation.
- Commission out and manage the **evaluation of Cytosponge**. Quarterly evaluation reports.
- Provide **evaluation support to the Living With and Beyond Cancer (LWBC) team**.
- Undertake a small scale **literature review of Quality of Life (QOL)** exploring which interventions are most (cost) effective in improving QOL.
- Provide light touch advice on how to **evaluate BRCA screening** to inform a full evaluation study in 22/23 if appropriate.
- Assessment of the **Lynch implementation guidance**.

DELIVERABLES													
Project	Activity/deliverable	Q1			Q2			Q3			Q4		
		April	May	June	July	Aug	Sept	Oct	Nov	Dec	Jan	Feb	March
Evaluation advice on BRCA	Explore the options for evaluating BRCA												
	Produce a report for the ED team												✓
National evaluation of the Targeted Lung Health Checks programme	Quality assurance of aggregated MI data and support sites with improvement												
	Management Information reports	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
	Quarterly progress reports		✓			✓			✓			✓	
	Quality assurance of all outputs												
National evaluation of Rapid Diagnostics Centres	Management Information reports	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
	Quarterly progress reports	✓			✓			✓			✓		
	Quality assurance of all outputs												
Evaluation of the CCE	Quarterly progress reports			✓			✓			✓			✓
	Report summarising key findings for national team and CCE pilots												✓
	Interviews with staff for service evaluation												
	Service evaluation report			✓									
	Commisison out patient experience strand												
	Deliver patient experience summary report										✓		
	Management Information reports for national team and CCE pilots	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Assessment of Lynch implementation guidance	Undertake a review of how the guidance is being implemented												
	Report summarising how the Lynch guidance is being applied												✓
QOL literature review	Support the personalised care team to commission out a rapid evidence assessment												
Evaluation support to LWBC	Provide evaluaion support including scoping out a full evaluation in Q4												
	Evaluation specification												✓
Cytosponge evaluation	Commission an external evaluator												
	Management of evaluation contract Evaluation strategy & quarterly progress reports						✓			✓		✓	